Cancer Pain and Opioid Use Disorder

ABSTRACT

Opioid use dysfunction (OUD) is more and more acknowledged and co-present in sufferers with most cancers. Sadly, OUD will not be addressed or handled adequately in oncology settings. As well as, sufferers with cancer-related ache handled with narcotic ache medicines are in danger for nonmedical opioid use (NMOU). Greater than two-thirds of sufferers with superior most cancers have ache. Each OUD and NMOU should be concomitantly addressed alongside cancer-related ache administration to keep away from issues corresponding to overdose. We assessment the method to figuring out and treating OUD and NMOU in sufferers with most cancers and cancer-related ache.

Introduction

Primum non nocere. It’s troubling to suppose that the medicines, opioids particularly, meant to alleviate ache and struggling could inadvertently trigger extra hurt than good. Nonetheless, the harms attributable to inappropriate opioid prescribing have been effectively documented within the noncancer inhabitants and assist information opioid prescribing in sufferers with most cancers.¹ Of the cardinal moral ideas of medical care, respect for nonmaleficence could be notably difficult when the car of offering symptomatic reduction for a lot of sufferers carries the burden of habit for some. On a nationwide scale, responses to the opioid epidemic recapitulate related anxieties about managing ache within the face of substance use issues.²

Pain is extremely prevalent in all sufferers with most cancers (30%-50%); its presence is very related for sufferers with superior most cancers (roughly 70%) managed primarily by medical
oncologists.³ Given the excessive lifetime prevalence of substance use issues, many sufferers who develop most cancers may have a preexisting opioid use dysfunction (OUD), and many extra sufferers shall be liable to nonmedical opioid use (NMOU) and different types of what has been termed chemical coping.^4,5 Nonmedical opioid use encompasses a broad spectrum of nonprescribed opioid use that’s notably related for sufferers with most cancers who additionally expertise ache. The definition comes from the US Nationwide Survey on Drug Use and Well being and consists of use of opioids and not using a prescription, use with a prescription however not as prescribed, or use supposed primarily for the needs of the expertise of feeling attributable to opioids.⁶ According to the growing prevalence of OUD within the normal inhabitants, a rise in opioid-associated deaths was noticed in sufferers with most cancers particularly from 2006 to 2016.⁷ As well as, sufferers could develop OUD throughout or after their remedy for most cancers. Due to this fact, screening, assessments, and discussions about substance use ought to be routine and its administration seamless given the logistical nuances of most cancers care.⁵

The co-emergence of most cancers and OUD develops from (1) sufferers with a historical past of OUD or different substance use issues who develop most cancers or (2) sufferers with most cancers who develop OUD. The latter group originates from the iatrogenic growth of OUD. Sadly, the iatrogenic contribution of opioid publicity to OUD and its etiology are usually not effectively understood.⁸ Though iatrogenic growth of OUD represents the minority of OUD, it definitely warrants additional analysis. Even nonetheless, many sufferers taking opioids is not going to belong to both group however could also be at excessive danger for NMOU, particularly given the excessive prevalence of psychosocial stressors in sufferers with most cancers.

Herein we assessment methods for the administration of ache in sufferers with most cancers and concomitant OUD, both preexisting or growing whereas being handled for ache, and methods for ache administration in sufferers with most cancers who’re at excessive danger for NMOU.

Strategies

We carried out complete searches of PubMed and Google Scholar for all related publications about OUD, extra particularly in sufferers with most cancers ache, utilizing the next key phrases: oncology, most cancers, opioid, opioid disaster, ache, palliation, opioid misuse, dependence, opioid use dysfunction. We centered totally on the research that described oncological ache together with opioid use and present pharmacologic therapies to handle OUD. We excluded abstracts, feedback, and non–English language articles.

Screening for Aberrant Opioid Use

Scientific apply guideline suggestions for lively screening and monitoring of opioid ache administration are conspicuously incomplete regardless of the significance of opioids to deal with most cancers ache and the chance of aberrant use.⁵ A descriptive research of ache administration practices discovered that clinicians have been much less seemingly to make use of urine toxicology screening whereas prescribing opioids or refuse opioid prescriptions for sufferers with most cancers vs noncancer sufferers.⁹ The Nationwide Complete Cancer Community (NCCN) recommends the usage of Threat Analysis and Mitigation Technique instruments which have been put in place and are FDA accredited for particular person opioid merchandise.¹⁰ The NCCN recommends utilizing state-run prescription drug monitoring packages and that clinicians are educated on aberrant use behaviors.¹⁰ Briefly, these embrace such behaviors as compulsive use and preoccupation, overt cravings, and lack of management, in addition to continued use regardless of hurt.¹¹ Along with affected person schooling relating to opioid merchandise and evaluating therapeutic response to opioids, the NCCN additionally recommends evaluating sufferers for danger elements related to opioid misuse/abuse/diversion and monitoring for opioid misuse and abuse. Screening instruments can be found for this function however are usually not particular to cancer-related ache administration.¹² A historical past of illicit drug, alcohol, or substance dependence, along with a household historical past of substance abuse, signifies increased danger of aberrant opioid use. As well as, youthful sufferers with a historical past of authorized issues, incarceration, or psychiatric issues corresponding to posttraumatic stress dysfunction, bipolar dysfunction, nervousness, and despair have an elevated danger of aberrant opioid treatment use.¹² The NCCN guideline suggestions encourage sufferers with a historical past of habit to be handled for cancer-related ache in coordination with an habit specialist. As well as, sufferers with high-risk elements for opioid misuse profit from psychosocial schooling, assist providers, and cognitive habits therapies that handle problem-solving methods and methods to cut back the influence of modifiable danger elements.¹⁰ Clinicians ought to take into account interdisciplinary collaborations, together with early referrals to interventional ache specialists, to maximise the usage of nonopioid methods for ache reduction. Outpatient visits ought to be frequent, corresponding to weekly, if attainable, to cut back the amount of prescribed opioids at any given time level.

Analysis of Psychosocial Stressors

A world signs evaluation is crucial for complete ache administration as a result of despair, nervousness, and psychological misery worsen the severity, tolerability, and chronicity of perceived ache. On the similar time, to be in ache is to be distressed, which can precipitate or worsen nervousness and despair. Additionally, despair lowers ache tolerance.¹³ Issues, together with modifications in patterns of sleep, cognition, character, or different substance use issues, are each causes and penalties on this round course of that characterizes what has been termed complete ache by palliative care founder Dame Cicely Saunders.^14-16 The aim of structured symptom assessments is to untangle the bidirectional relationship between painful circumstances and psychological well being and determine areas of dysfunction the place intervention could lower struggling.

Sufficient administration of OUD, along with cancer-related ache, requires acceptable consideration to the constellation of concomitant neuropsychiatric signs (eg, despair, nervousness, insomnia, cognitive impairment) that usually accompany ache. The American Society of Scientific Oncology and the NCCN have put forth guideline suggestions for screening and remedy of those signs.^10,17 Though concomitant psychiatric signs could abate whereas adequately addressing ache, it’s typically advisable each are handled concomitantly. Psychoeducation performs a job in serving to sufferers perceive the relationships amongst ache, despair, insomnia, and poor govt operate, for instance. Sufferers ought to have an thought of when they’re experiencing nervousness, for instance, within the setting of ache or by itself, to facilitate the administration of as-needed medicines. As well as, clinicians who deal with cancer-related ache,
particularly within the setting of OUD, ought to have the ability to readily acknowledge affective issues (eg, despair, nervousness) and cognitive issues (eg, delirium). Diagnostic uncertainty and remedy trepidation ought to be met with immediate referral to psychological well being clinicians and symptom specialists. Complete screening instruments can expedite recognition and remedy of those concomitant symptom clusters.

Psychosocial screeners and multisymptom evaluation instruments ought to be collected concomitantly with opioid danger evaluation instruments, such because the Opioid Threat Software or the Screener Opioid Evaluation for Sufferers with Pain.^18,19 Psychological misery, nervousness, and despair may very well be assessed utilizing the Misery Thermometer and Downside Listing, the Edmonton Symptom Evaluation Scale, or PROMIS (Affected person-Reported Outcomes Measurement Data System) measures. PROMIS measures can be utilized to evaluate many psychosocial signs. They’re derived from legacy measures and are validated in most cancers settings. Insomnia could also be addressed by questioning sleep hygiene habits and assessing for preliminary, center, and terminal insomnia patterns. Cognitive impairment and delirium ought to be assessed by a number of time level assessments of consciousness, orientation, and consideration. A number of temporary self-report and clinician-administered scales measure consideration and consider for cognitive impairment. The evaluation of alcohol and different substance use issues could also be achieved utilizing PROMIS measures, and the CAGE (lower down, aggravated, responsible, eye-opener) screener for alcohol use could also be prolonged to incorporate substance use.²⁰ As well as, well-performing abbreviated and single-item screeners can be found for alcohol (Alcohol Use Problems Identification Check Consumption)²¹ and different drug²² use, which may set off additional screening with the total Alcohol Use Problems Identification Check or referral to remedy.

Case Presentation

A 57-year-old man is being handled for recurrent small cell lung most cancers with third-line chemotherapy. He notes growing bony ache requiring escalating doses of short-acting hydromorphone along with the extended-release morphine formulation he’s already taking. Along with ache from bony metastasis, he has numerous psychological considerations, corresponding to nervousness (seemingly precipitated by shortness of breath), preliminary and terminal insomnia, fatigue, and reminiscence impairment. His clinicians have change into pissed off with what appears to be inconsistent and extreme use of as-needed short-acting hydromorphone as he admitted taking greater than prescribed to assist with sleep and nervousness.

The affected person has no private or household historical past of drug use or alcoholism. He denies different vital psychosocial stressors except for having lung most cancers. Common screening reveals the presence of partially handled ache, no proof of cognitive impairment or delirium, a optimistic urine drug display screen for opioids, and the presence of extreme insomnia, nervousness, and depressive signs.

Nonmedical Opioid Use

The Nationwide Institute on Drug Abuse defines NMOU as “taking an opioid in a way or dose aside from prescribed, taking another person’s prescription opioid, even when for a legit medical motive, or taking prescription opioids for the sentiments that it produces.”²³ Chemical coping and NMOU are associated ideas. Chemical coping refers to the usage of opioid medicines to deal with psychological struggling or emotional misery.²⁴ It’s a controversial time period that was first used to described drug-seeking behaviors of sufferers with end-stage alcoholism.²⁵ This nomenclature could also be skilled as stigmatizing, and, subsequently, it could be extra useful and acceptable to handle unresolved misery. In fact, ache is intimately associated to psychological misery. Pain reduction could alleviate misery; subsequently, sufferers could use opioids in extra of what’s wanted to deal with ache if misery can be ameliorated vis-à-vis opioid treatment. Schooling relating to acceptable use of opioids and enough screening for psychological comorbidities are key ideas for addressing NMOU and chemical coping. Nonmedical opioid use could happen as a type of chemical coping or opioid use for different non–pain-related causes. It could end result from opioid availability and lack of psychological well being useful resource or psychoeducation availability, and the presence of psychological well being stigma. Oversight of NMOU and chemical coping requires not solely limiting opioid treatment availability but additionally offering wanted psychoeducation, screening and triaging for psychosocial misery, and making nonstigmatizing psychological well being referrals. Actually, assessing for NMOU is a chance to evaluate psychosocial misery as effectively.

The issue with NMOU is the inappropriate use of doubtless harmful and addictive treatment to suboptimally deal with psychological signs. Anxiousness, despair, and insomnia are extra safely and successfully handled with acceptable (non)psychopharmacologic brokers to focus on these signs. This syndrome is extra widespread amongst younger, male sufferers with a historical past of alcohol use, drug use, and smoking.^26,27 Sufferers who quickly escalate the opioid dose, continuously complain of ache with depth of 10 of 10, or are in danger for chemical coping ought to be referred to a supportive care/palliative care crew for interdisciplinary administration normally consisting of a ache administration specialist and counselors. Addressing probably the most pertinent challenge ought to assist restrict chemical coping and NMOU. At different instances, sufferers may have a identified historical past of OUD, which can be uncovered or develop whereas coping with the stresses of most cancers. By definition, sufferers with OUD are at excessive danger for dropping management of their opioid use and may have increased charges of different psychosocial elements that typically make ache extra extreme, and they are usually extra illiberal of ache (this abates to some extent when they’re handled for OUD), requiring increased doses of opioids for ache management. Sufferers with OUD ought to be handled for OUD whereas receiving remedy for cancer-related ache.²⁸

Within the case presentation, it’s seemingly that NMOU would abate with psychoeducation and adequately addressing nervousness, despair, and insomnia.

Opioid Use Disorder

An individual is outlined as having an OUD when there’s a pathologic sample of behaviors associated to opioid use, which is a mixture of cognitive, behavioral, and physiologic signs.²⁹ The individual continues substance use regardless of rising substance-related issues, which causes vital impairment or misery. The total diagnostic standards are given in Desk 1. A affected person should meet at the very least 2 diagnostic standards, and severity is stratified as delicate, reasonable, or extreme in the event that they meet 2 or 3, 4 or 5, or greater than 6, respectively. A limitation of those diagnostic standards is that severity is predicated on frequency of standards moderately than on impairment. An individual might meet 7 standards (extreme) but have little purposeful impairment, and another person might meet 3 standards (delicate) and have vital purposeful impairment.

Tolerance or withdrawal (typically termed physiologic dependence) could happen throughout the suitable use of opioid therapies and shouldn’t be counted towards a analysis of OUD when opioids are used solely below acceptable medical supervision. As a result of many clinicians and sufferers are involved with the opportunity of opioid dependence, this can be a key distinction that’s diagnostically related. Moreover, many sufferers exhibit indicators of pseudoaddiction, a time period coined in 1989 by Weissman and Haddox³⁰ to explain an “iatrogenic syndrome that mimics the behavioral signs of habit” in sufferers with insufficient ache management. Though the existence of pseudoaddiction, as outlined, is controversial, the idea stays current within the medical literature and appears to focus on a clinically related idea. These sufferers are normally recognized by notable behaviors corresponding to demanding particular opioids to deal with their ache or different traditional indicators of drug-seeking habits, however these behaviors ought to stop as soon as enough ache management is achieved. Due to this fact, patterns of drug use, together with route of administration (intravenous or intranasal), frequency, impairment (ie, social, private, skilled), and different substance use ought to be explored.

An entire historical past with vital collateral info is required to entertain a analysis of OUD: a bodily examination along with full social and psychological well being histories ought to be acquired from the affected person.³¹ The bodily examination could reveal a affected person in intoxication (confusion, miosis, hypersomnia, nausea, euphoria, constipation, decreased ache notion) or withdrawal. Urine drug checks are vital throughout preliminary and follow-up visits to determine the kind of opioid substance used and different comorbid substance use, in addition to to observe remission and upkeep.³² In most areas it’s now vital to incorporate urine testing for fentanyl, which is commonly not included in normal urine drug check batteries.³³ If the affected person has a historical past of intravenous drug use, checks corresponding to infectious screening (HIV, hepatitis B, hepatitis C) are advisable; echocardiography to rule out endocarditis ought to be ordered for these with a historical past of bacteremia.³¹

Advanced persistent opioid dependence (CPOD) can develop from long-term opioid dependence and shares many options with OUD, together with the organic mechanisms related to UOD. Advanced persistent opioid dependence develops within the setting of opioid remedy that has not been efficient however doesn’t meet the factors for OUD. It exists on a continuum between easy bodily dependence and OUD. Advanced persistent opioid dependence ought to be thought of when long-term opioid use and tapering are usually not efficient. Apparently, CPOD could reply to buprenorphine remedy, which may also be utilized in a persistent ache setting. Delineating the diagnostic entity related to dysfunctional or inappropriate opioid use has underlying remedy implications. Universally, psychosocial elements, together with nonpharmacologic administration of ache, ought to be thought of in all cancer-related ache remedy plans.

Administration of Opioid Therapies in Sufferers With Cancer Who Have OUD

Provided that roughly one-half of sufferers with most cancers have been prescribed an opioid through the 12 months of their preliminary analysis, secure and efficient ache administration must be achieved whereas contemplating the administration of OUD. Though the main focus of this assessment is secure opioid prescribing in sufferers with OUD, one would possibly take into account the phenomenon of opioid misuse as a continuum, with chemical coping, NMOU, or CPOD being an early stage of substance use issues.^34,35 Within the early phases when sufferers use opioids to deal with nervousness, despair, or sleep issues, these actions can typically be countered with compassionate use of motivational interviewing to help them in gaining perception into their behaviors and to appropriately deal with their emotional misery. Early identification is important.^35,36 The most cancers setting (eg, kind, stage) and whether or not the affected person is being handled with healing intent play a job in prediction of ongoing ache and concomitant neuropsychiatric signs. Though early identification of ache, together with enough remedy methods, are nonetheless paramount, the concomitant concerns range based mostly on remedy setting. Within the healing setting, the clinician could also be most apprehensive about addressing cancer-related ache and OUD to facilitate adherence with anticancer remedies, whereas high quality of life and symptom administration could also be additional prioritized within the palliative setting.

As well as, nonpharmacologic measures ought to be instituted simply as could be acceptable for a affected person with most cancers however with out OUD. These modalities embrace psychoeducation relating to
exercise and addressing ache administration methods proactively, train remedy as tolerated, mindfulness and stress discount, group assist actions, spinal manipulation, acupuncture, yoga, and different multimodal integrative therapies, in addition to nonopioid analgesics corresponding to nonsteroidal anti-inflammatory medication, chosen anticonvulsants (eg, gabapentin and pregabalin), and chosen antidepressants (eg, duloxetine for peripheral neuropathy, amitriptyline for insomnia and irritable bowel syndrome varieties of ache).^37-39 Regardless of the widespread use of medical marijuana in sufferers with most cancers and its potential use in addressing OUD, the proof base is missing, and, subsequently, medical marijuana can’t be advisable to offset opioid-based medicines for OUD (MOUDs).^40,41

Sufferers with ongoing, untreated substance use issues require extra complicated care than can normally be offered in an oncology setting with out vital interdisciplinary assist.⁴² The objective would be the provision of ache management whereas utilizing “hurt discount,” which implies the best degree of secure and efficient care. The priorities of the hurt discount mannequin of look after OUD are prevention of overdose and different penalties of unsafe use (eg, accidents, infections), elevated management over use (ie, lowering the full quantity used), and stopping diversion.⁴³ Per week’s provide of opioid could also be prescribed, moderately than 1 month, and frequent urine screening could also be used. Interdisciplinary care is warranted. Moreover, individuals with a medical historical past of substance use dysfunction and those that are in restoration could current a novel problem. Fears of relapse when introduced with an opioid for the remedy of most cancers ache could lead the affected person to refuse these medicines. Obtainable proof doesn’t assist an elevated danger of relapse for sufferers handled with opioid analgesics who’re maintained on medicines for OUD.^44-46
Having considerate discussions about use of opioids, attempting nonopioid analgesics, utilizing interventional therapies, and incorporating the affected person’s sponsor or case supervisor might help present efficient reduction whereas limiting the chance of relapse.

At the moment, there are 2 evidence-based MOUDs: buprenorphine and methadone, that are additionally accredited for ache.^47,48 Buprenorphine acts as a partial mu receptor agonist with excessive affinity and gradual dissociation and could precipitate withdrawal as it could displace different opioids. It’s mixed with naloxone in most formulations accredited for OUD, to stop inhalation or injection use of the merchandise. Methadone is a full mu receptor agonist with a protracted half-life. Each medicines blunt euphoria, lower craving, and are medically secure. They scale back danger of overdose, acute and persistent infections, and suicide.^49,50 Usually, sufferers with most cancers have at the very least double the chance of suicide, however the danger turns into exceedingly pronounced with ache and the primary few weeks to months after analysis or different cancer-related crises.⁵¹ Buprenorphine and methadone have totally different dosing schedules for OUD remedy and analgesia: for ache administration, they’re prescribed at decrease doses a number of instances day by day, versus once-daily dosing for OUD. Use of those medicines to deal with OUD is extremely regulated. Buprenorphine prescribers have to obtain a Drug Enforcement Company waiver with limitations on the variety of sufferers to be enrolled within the clinic, whereas methadone upkeep remedy have to be administered in a federally accredited remedy program. These restrictions don’t apply to prescriptions supposed to deal with ache. There’s a dearth of proof relating to twin remedies for co-occurring OUD and most cancers ache. Due to this fact, in 2021, Merlin and colleagues⁵² performed a web-based modified Delphi method to develop consensus for managing most cancers ache in sufferers with OUD from specialists within the self-discipline of hospice and palliative drugs, ache drugs, and habit drugs. Specialists agreed that nonopioid pharmacologic and nonpharmacologic remedies ought to be maximized earlier than changes of MOUDs. The abstract of the advice is highlighted in Desk 2.

In each circumstances, specialists agreed that it could be inappropriate to modify buprenorphine-naloxone to a methadone upkeep remedy program, and vice versa. Specialists advised switching buprenorphine-naloxone to separate doses of methadone as acceptable on account of perceived weaker ache management, though analysis by Neumann and colleagues⁵³ has proven each medicines to be equally analgesic when initiated in sufferers recognized as being hooked on different opioids. Stopping OUD remedy fully and beginning a full agonist opioid was discouraged.

Sufferers who’re taking a full agonist opioid to deal with most cancers ache however who additionally meet the factors for OUD could profit from a swap to methadone or buprenorphine as a main analgesic remedy. Usually, sufferers are reluctant to modify ache medicines on account of considerations of insufficient ache management. It is very important reassure sufferers that good options exist, and physicians ought to concentrate on addressing the affected person’s ache administration whereas additionally lowering potential adversarial results from full agonist opioids and unsafe drug use. If the affected person is keen to think about buprenorphine, a low-dose initiation protocol could be applied to stop withdrawal signs.⁵⁴ Edens et al^47,55 current their residence buprenorphine initiation protocol, which has been proven to attenuate adversarial results and attain therapeutic doses for each ache administration and OUD by day 5 (Desk 3).

Regardless of the advice that sufferers with OUD and cancer-related ache proceed taking MOUDs, there are conditions by which the clinician may have to think about additionally prescribing a full opioid agonist (Sidebar). For sufferers already established on MOUDs, mechanisms of tolerance and hyperalgesia could forestall enough analgesia from buprenorphine or methadone alone.⁵⁶ Uncontrolled ache performs a big position in sufferers with OUD returning to or persevering with opioid use.⁴⁶ Concurrent prescribing of a short-term full agonist has been proven to cut back withdrawal and craving, handle ache adequately, and forestall sufferers from turning to illicitly obtained opioids.⁵⁷ From a hurt discount perspective, compassionate, efficient care by means of enough ache administration minimizes the dangers of unsupervised opioid use.

Conclusion

Administration of cancer-related ache in sufferers who’ve OUD or are in danger for OUD requires an individualized method based mostly on the affected person’s substance use historical past and ache administration wants. Along with making an correct analysis of substance use dysfunction, a complete evaluation and an understanding of opioid and MOUD therapies are vital to supply enough patient-centered ache administration. Clinicians ought to be conscious that opioids is likely to be misused, both inadvertently (eg, for its hypnotic and anxiolytic results) or purposefully by these with substance use issues; nonetheless, compassionate care and hurt avoidance ideas will assist the cautious use of opioid medicines when nonopioid and nonpharmacologic choices are insufficient.

Acknowledgments:

Battle of Pursuits: No battle of curiosity reported by authors. We’ve got reviewed and accredited the manuscript as it’s submitted and don’t have any battle of curiosity to declare. Moreover, every creator met every of the authorship necessities as said within the Uniform Necessities for Manuscripts Submitted to Biomedical Journals. We had a number of roles in writing the manuscript together with the conception, design, acquisition, evaluation and interpretation of the info. The data within the manuscript has not been revealed beforehand and will not be into account for publication elsewhere.

Writer affiliations:

Amvrine Ganguly, MD^1,¥; Marco Michael, MD^1,¥; Simona Gorschin, MD²; Kirk Harris, MD³; and Daniel McFarland, DO^2,4

^¥co-first authors

¹Division of Psychiatry and Behavioral Sciences, State College of New York Downstate Brooklyn

²Division of Psychiatry and Behavioral Sciences, Lenox Hill Hospital, Northwell Well being, New York, NY

³Division of Psychiatry, College of Rochester, Rochester, NY

⁴Division of Drugs (DM), Lenox Hill Hospital, Northwell Well being, New York, NY

Contact Data:

Daniel C. McFarland, DO
Division of Psychiatry and Behavioral Sciences
Lenox Hill Hospital, Northwell Well being
New York, NY 10034.
E mail: danielcurtismcfarland@gmail.com

References

1. Humphreys Ok, Shover CL, Andrews CM, et al. Responding to the opioid disaster in North America and past: suggestions of the Stanford-Lancet Fee. Lancet. 2022;399(10324):555-604. doi:10.1016/S0140-6736(21)02252-2
2. Bates N, Bello JK, Osazuwa-Peters N, Sullivan MD, Scherrer JF. Melancholy and long-term prescription opioid use and opioid use dysfunction: implications for ache administration in most cancers. Curr Deal with Choices Oncol. 2022;23(3):348-358. doi:10.1007/s11864-022-00954-4
3. van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Excessive prevalence of ache in sufferers with most cancers in a big population-based research in The Netherlands. Pain. 2007;132(3):312-320. doi:10.1016/j.ache.2007.08.022
4. Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and remedy of opioid misuse and habit: a assessment. JAMA Psychiatry. 2019;76(2):208-216. doi:10.1001/jamapsychiatry.2018.3126
5. Carmichael AN, Morgan L, Del Fabbro E. Figuring out and assessing the chance of opioid abuse in sufferers with most cancers: an integrative assessment. Subst Abuse Rehabil. 2016;7:71-79. doi:10.2147/SAR.S85409
6. Ulker E, Del Fabbro E. Finest practices within the administration of nonmedical opioid use in sufferers with cancer-related ache. Oncologist. 2020;25(3):189-196. doi:10.1634/theoncologist.2019-0540
7. Chino FL, Kamal A, Chino JP. Opioid-associated deaths in sufferers with most cancers: a inhabitants based mostly research of the opioid epidemic over the previous 10 years 2018. J Clin Oncol. 2018;36(suppl 30):230. doi:10.1200/JCO.2018.36.30_suppl.230
8. Beauchamp GA, Nelson LS, Perrone J, Lyons MS. A theoretical framework and nomenclature to characterize the iatrogenic contribution of therapeutic opioid publicity to opioid induced hyperalgesia, bodily dependence, and opioid use dysfunction. Am J Drug Alcohol Abuse. 2020;46(6):671-683. doi:10.1080/00952990.2020.1778713
9. Liebling D, Mehta N, Gulati A. Opioid screening practices within the most cancers ache affected person. J Palliat Med. 2019;22(1):10-17. doi:10.1089/jpm.2018.0168
10. Dans M, Kutner JS, Agarwal R, et al. NCCN Tips(R) Insights: Palliative Care, Model 2.2021. J Natl Compr Canc Netw. 2021;19(7):780-788. doi:10.6004/jnccn.2021.0033
11. Kwon JH, Tanco Ok, Hui D, Reddy A, Bruera E. Chemical coping versus pseudoaddiction in sufferers with most cancers ache. Palliat Assist Care. 2014;12(5):413-417. doi:10.1017/S1478951513001351
12. Anghelescu DL, Ehrentraut JH, Faughnan LG. Opioid misuse and abuse: danger evaluation and administration in sufferers with most cancers ache. J Natl Compr Canc Netw. 2013;11(8):1023-1031. doi:10.6004/jnccn.2013.0120
13. Marazziti D, Castrogiovanni P, Rossi A, et al. Pain threshold is diminished in despair. Int J Neuropsychopharmacol. 1998;1(1):45-48. doi:10.1017/S1461145798001047
14. Tang J, Gibson SJ. A psychophysical analysis of the connection between trait nervousness, ache notion, and induced state nervousness. J Pain. 2005;6(9):612-619. doi:10.1016/j.jpain.2005.03.009
15. Kroenke Ok, Wu J, Bair MJ, Krebs EE, Damush TM, Tu W. Reciprocal relationship between ache and despair: a 12-month longitudinal evaluation in main care. J Pain. 2011;12(9):964-973. doi:10.1016/j.jpain.2011.03.003
16. Schneider E, Linden M, Weigmann H, et al. Early discount in painful bodily signs is related to enhancements in long-term despair outcomes in sufferers handled with duloxetine. BMC Psychiatry. 2011;11:150.
17. ASCO Tips: Screening, Evaluation, and Care of Anxiousness and Depressive Signs in Adults with Cancer. American Society of Scientific Oncology. Revealed 2014. Accessed Month, day 2022. https://bit.ly/3RUg060
18. Butler SF, Budman SH, Fernandez KC, Fanciullo GJ, Jamison RN. Cross-validation of a screener to foretell opioid misuse in persistent ache sufferers (SOAPP-R). J Addict Med. 2009;3(2):66-73. doi:10.1097/ADM.0b013e31818e41da
19. Reyes-Gibby CC, Anderson KO, Todd KH. Threat for opioid misuse amongst emergency division most cancers sufferers. Acad Emerg Med. 2016;23(2):151-158. doi:10.1111/acem.12861
20. Yennurajalingam S, Edwards T, Arthur JA, et al. Predicting the chance for aberrant opioid use habits in sufferers receiving outpatient supportive care session at a complete most cancers middle. Cancer. 2018;124(19):3942-3949. doi:10.1002/cncr.31670
21. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a quick display screen for alcohol misuse in main care. Alcohol Clin Exp Res. 2007;31(7):1208-1217. doi:10.1111/j.1530-0277.2007.00403.x
22. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening check for drug use in main care. Arch Intern Med. 2010;170(13):1155-1160. doi:10.1001/archinternmed.2010.140
23. Prescription Opioids DrugFacts. Nationwide Institutes of Well being. Revealed June 2021. Accessed June 15, 2022. https://bit.ly/3Bbac1K
24. Kwon JH, Hui D, Bruera E. A pilot research to outline chemical coping in most cancers sufferers utilizing the delphi technique. J Palliat Med. 2015;18(8):703-706. doi:10.1089/jpm.2014.0446
25. Strasser F, Walker P, Bruera E. Palliative ache administration: when each ache and struggling harm. J Palliat Care. 2005;21(2):69-79.
26. Nguyen LM, Rhondali W, De la Cruz M, et al. Frequency and predictors of affected person deviation from prescribed opioids and boundaries to opioid ache administration in sufferers with superior most cancers. J Pain Symptom Handle. 2013;45(3):506-516. doi:10.1016/j.jpainsymman.2012.02.023
27. Del Fabbro E. Evaluation and administration of chemical coping in sufferers with most cancers. J Clin Oncol. 2014;32(16):1734-1738. doi:10.1200/JCO.2013.52.5170
28. Pergolizzi JV Jr, Magnusson P, Christo PJ, et al. Opioid remedy in most cancers sufferers and survivors vulnerable to habit, misuse or complicated dependency. Entrance Pain Res (Lausanne). 2021;2:691720. doi:10.3389/fpain.2021.691720
29. American Psychiatric Affiliation. Diagnostic and Statistical Handbook of Psychological Problems. fifth ed. American Psychiatric Affiliation; 2013.
30. Weissman DE, Haddox DJ. Opioid pseudoaddiction: an iatrogenic syndrome. Pain. 1989;36(3):363-366. doi:10.1016/0304-3959(89)90097-3
31. Dydyk AM, Jain NK, Gupta M. Opioid use dysfunction. In: StatPearls [Internet]. StatPearls Publishing; 2022. Accessed March 7, 2022. https://bit.ly/3Owa6ou
32. Johnson RE, Pressure EC, Amass L. Buprenorphine: the right way to use it proper. Drug Alcohol Rely. 2003;70(suppl 2):S59-S77. doi:10.1016/s0376-8716(03)00060-7
33. Dezman ZDW, Felemban W, Bontempo LJ, Want ED. Proof of fentanyl use is widespread and continuously missed in a cross-sectional research of emergency division sufferers in Baltimore, Maryland. Clin Toxicol (Phila). 2020;58(1):59-61. doi:10.1080/15563650.2019.1605078
34. Castaneda AM, Lee CS, Kim YC, Lee D, Moon JY. Addressing opioid-related chemical coping in long-term opioid remedy for persistent noncancer ache: a multicenter, observational, cross-sectional research. J Clin Med. 2018;7(10):354. doi:10.3390/jcm7100354
35. Yennurajalingam S, Arthur J, Reddy S, et al. Frequency of and elements related to nonmedical opioid use habits amongst sufferers with most cancers receiving opioids for most cancers ache. JAMA Oncol. 2021;7(3):404-411. doi:10.1001/jamaoncol.2020.6789
36. Bruera E, Paice JA. Cancer ache administration: secure and efficient use of opioids. Am Soc Clin Oncol Educ E book. 2015:e593-e599. doi:10.14694/EdBook_AM.2015.35.e593
37. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2009;15(13):1548-1553. doi:10.3748/wjg.15.1548
38. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, persistent ache or fibromyalgia. Cochrane Database Syst Rev. 2014(1):CD007115. doi:10.1002/14651858.CD007115.pub3
39. Smith EM, Pang H, Cirrincione C, et al. Impact of duloxetine on ache, operate, and high quality of life amongst sufferers with chemotherapy-induced painful peripheral neuropathy: a randomized medical trial. JAMA. 2013;309(13):1359-1367. doi:10.1001/jama.2013.2813
40. Wiese B, Wilson-Poe AR. Rising proof for hashish’ position in opioid use dysfunction. Hashish Cannabinoid Res. 2018;3(1):179-189. doi:10.1089/can.2018.0022
41. Suzuki J, Weiss RD. Cannabinoids for the remedy of opioid use dysfunction: the place is the proof? J Addict Med. 2021;15(2):91-92. doi:10.1097/ADM.0000000000000711
42. Kircher S, Zacny J, Apfelbaum SM, et al. Understanding and treating opioid habit in a affected person with most cancers ache. J Pain. 2011;12(10):1025-1031. doi:10.1016/j.jpain.2011.07.006
43. Taylor JL, Johnson S, Cruz R, Grey JR, Schiff D, Bagley SM. Integrating hurt discount into outpatient opioid use dysfunction remedy settings: hurt discount in outpatient habit remedy. J Gen Intern Med. 2021;36(12):3810-3819. doi:10.1007/s11606-021-06904-4
44. Kantor TG, Cantor R, Tom E. A research of hospitalized surgical sufferers on methadone upkeep. Drug Alcohol Rely. 1980;6(3):163-173. doi:10.1016/0376-8716(80)90455-x
45. Manfredi PL, Gonzales GR, Cheville AL, Kornick C, Payne R. Methadone analgesia in most cancers ache sufferers on persistent methadone upkeep remedy. J Pain Symptom Handle. 2001;21(2):169-174. doi:10.1016/s0885-3924(00)00252-9
46. Karasz A, Zallman L, Berg Ok, Gourevitch M, Selwyn P, Arnsten JH. The expertise of persistent extreme ache in sufferers present process methadone upkeep remedy. J Pain Symptom Handle. 2004;28(5):517-525. doi:10.1016/j.jpainsymman.2004.02.025
47. Edens EL, Abelleira A, Declan B, Becker WC. You say ache. I say habit. Let’s name the entire thing off. Psychiatric Instances. Revealed November 9, 2020. Accessed March 7, 2022. https://bit.ly/3v8bN4T
48. Hanna V, Senderovich H. Methadone in ache administration: a scientific assessment. J Pain. 2021;22(3):233-245. doi:10.1016/j.jpain.2020.04.004
49. Mooney LJ. Medicine remedy for opioid use dysfunction reduces suicide danger. Am J Psychiatry. 2022;179(4):262-263. doi:10.1176/appi.ajp.20220173
50. Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of various remedy pathways for opioid use dysfunction. JAMA Netw Open. 2020;3(2):e1920622. doi:10.1001/jamanetworkopen.2019.20622
51. Ahn MH, Park S, Lee HB, et al. Suicide in most cancers sufferers inside the first 12 months of analysis. Psychooncology. 2015;24(5):601-607. doi:10.1002/pon.3705
52. Merlin JS, Khodyakov D, Arnold R, et al. Knowledgeable panel consensus on administration of superior cancer-related ache in people with opioid use dysfunction. JAMA Netw Open. 2021;4(12):e2139968. doi:10.1001/jamanetworkopen.2021.39968
53. Neumann AM, Blondell RD, Jaanimagi U, et al. A preliminary research evaluating methadone and buprenorphine in sufferers with persistent ache and coexistent opioid habit. J Addict Dis. 2013;32(1):68-78. doi:10.1080/10550887.2012.759872
54. Suen LW, Lee TG, Silva M, et al. Speedy overlap initiation protocol utilizing low dose buprenorphine for opioid use dysfunction remedy in an outpatient setting: a case sequence. J Addict Med. Revealed on-line February 10, 2022. doi:10.1097/ADM.0000000000000961
55. Becker WC, Frank JW, Edens EL. Switching from high-dose, long-term opioids to buprenorphine: a case sequence. Ann Intern Med. 2020;173(1):70-71. doi:10.7326/L19-0725
56. Alford DP, Compton P, Samet JH. Acute ache administration for sufferers receiving upkeep methadone or buprenorphine remedy. Ann Intern Med. 2006;144(2):127-134. doi:10.7326/0003-4819-144-2-200601170-00010
57. Thakrar AP. Quick-acting opioids for hospitalized sufferers with opioid use dysfunction. JAMA Intern Med. 2022;182(3):247-248. doi:10.1001/jamainternmed.2021.8111